Abstract 11555: Intra-Coronary Transfusion of Autologous CD34+ Cells Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease and Non Candidates for Coronary Artery Intervention---Results of Three Years Follow Up
Background: This study tested the hypothesis that “Intra-Coronary Transfusion of Autologous CD34+ Cells Effectively Reverses Myocardial Ischemia and Improves Left Ventricular Function in Patients with Diffuse Coronary Artery Disease and Non Candidates for Coronary Artery Intervention”.
Methods and results: 38 consecutive patients who matched the enrollment criteria have been consecutively recruited in the study within these three years. 100% of procedural safety and all patients were uneventful discharge from hospital. Flow cytometry showed that circulating level of endothelial progenitor cells (EPCs, i.e., CD34+ cells) were significantly higher with than without G-CSF treatment (all p<0.001). The EPCs were found to be continuously shed out from coronary sinus. The angiographic examination displayed 100% multi-vessel disease in these patients. 9-month angiographic follow-up showed markedly enhanced the small vessel density/neovascularization (mean increase = grade 2) as compared with prior to treatment (p<0.001). Both 3-D echo and cardiac MR imaging studies showed ≈ 4.0-5.0% of LVEF improvement at 6-moth follow-up (p <0.001). The improvement of angina and physical status were found to be more than 80% of the patients (p<0.0001). A positive correlation between coronary angiographic findings of angiogenesis grading and circulating level of VEGF as well as Matrigel assay for angiogenesis (all p<0.001). One-year survival rate was 100%. Only two patients died, one due to falling down to the ground with head injury, another one due to hyperkalemia (k+ level =7.9) during more long-term follow-up.
Conclusion: Intra-coronary autologous CD34+ Cell transfusion was safe and efficacious with significant heart function and clinical improvement during 3-year follow-up.
Key words: diffuse coronary artery disease, endothelial progenitor cells, heart function, clinical outcome [Clinical trial number: ISRCTN26002902 ]
- Stem cell therapy
- Coronary artery disease
- Ventricular function
- Clinical trials
- Percutaneous coronary intervention (PCI)
Author Disclosures: H. Yip: None. S. Leu: None. T. Tsai: None. J. Sheu: None. S. Chua: None.
- © 2014 by American Heart Association, Inc.